# XYLT2

## Overview
The XYLT2 gene encodes the enzyme xylosyltransferase 2, which is a crucial component in the biosynthesis of glycosaminoglycans (GAGs), such as heparan sulfate and chondroitin sulfate. These GAGs are vital for the formation of proteoglycans, which are essential for maintaining the structural integrity and function of the extracellular matrix. Xylosyltransferase 2 is categorized as a glycosyltransferase enzyme and is primarily active in the Golgi apparatus, where it catalyzes the transfer of xylose to serine residues on core proteins, initiating GAG chain elongation. The gene is expressed in various tissues, with significant activity in the liver, lung, and kidney, underscoring its importance in these organs (Cuellar2007Biosynthesis; Poönighaus2007Human). Mutations in the XYLT2 gene are linked to Spondyloocular syndrome, a disorder characterized by skeletal and ocular abnormalities, highlighting the clinical significance of this gene (Chouery2023Spondyloocular).

## Function
Xylosyltransferase 2 (XYLT2) is an enzyme that plays a critical role in the biosynthesis of glycosaminoglycans (GAGs), such as heparan sulfate and chondroitin sulfate, which are essential components of proteoglycans. XYLT2 catalyzes the initial and rate-limiting step in GAG biosynthesis by transferring xylose from UDP-xylose to serine residues on core proteins, initiating the formation of the tetrasaccharide linkage region necessary for GAG chain elongation (Fischer2020Xylosyltransferasedeficient; Poönighaus2007Human). This enzymatic activity is crucial for maintaining the structural integrity and function of the extracellular matrix, influencing processes such as cell adhesion, proliferation, and differentiation (Müller2012First).

XYLT2 is predominantly active in the Golgi apparatus of cells, where it facilitates the assembly of GAG chains on proteoglycans (Cuellar2007Biosynthesis). The enzyme is expressed in various tissues, with high levels in the liver, lung, and kidney, indicating its significant role in these organs (Poönighaus2007Human). The activity of XYLT2 is essential for normal cellular metabolism and viability, as evidenced by studies showing that its deficiency leads to reduced cell proliferation and increased cellular senescence (Fischer2020Xylosyltransferasedeficient).

## Clinical Significance
Mutations in the XYLT2 gene are associated with Spondyloocular syndrome (SOS), a rare autosomal recessive disorder characterized by skeletal and ocular abnormalities. Clinical features of SOS include generalized osteoporosis, multiple long bone fractures, platyspondyly, dense cataracts, retinal detachment, and dysmorphic facial features. Additional symptoms may include short stature, cardiopathy, hearing impairment, and intellectual disability (Chouery2023Spondyloocular; Doddato2021Spondyloocular). The condition is caused by biallelic mutations in the XYLT2 gene, which encodes the xylosyltransferase II enzyme, crucial for the biosynthesis of glycosaminoglycan chains in proteoglycans (Chouery2023Spondyloocular).

Various mutations have been identified, including frameshift and nonsense mutations, which can lead to more severe clinical presentations compared to missense mutations (Chouery2023Spondyloocular). The phenotypic severity of SOS may vary depending on the type and location of the mutation, although a clear genotype-phenotype correlation has not been established (Doddato2021Spondyloocular). Xylosyltransferase 2 deficiency affects the assembly of proteoglycans, impacting the development and maintenance of bone, cartilage, skin, and other tissues, leading to the multisystemic manifestations observed in SOS (Munns2015Homozygosity). Treatment options, such as bisphosphonate therapy, have shown some effectiveness in improving bone mineral density and reducing fracture frequency, although the exact mechanism remains unclear (Chouery2023Spondyloocular).

## Interactions
Xylosyltransferase 2 (XYLT2) is involved in the biosynthesis of glycosaminoglycans and interacts with various proteins and substrates in this process. XYLT2 has been shown to facilitate the xylosylation of serglycin (SRGN) when co-expressed in Nicotiana benthamiana plants, indicating a potential interaction between these proteins in the context of post-translational modification (Matsuo2018Xylosylation). This interaction is evidenced by the shift in mobility of SRGN-specific bands in SDS-PAGE analysis, suggesting that XYLT2 modifies SRGN to form a glycoprotein (Matsuo2018Xylosylation).

XYLT2 also interacts with heparin, a glycosaminoglycan, through electrostatic interactions. This binding can be disrupted by high salt concentrations, indicating that the interaction is primarily ionic (Casanova2009Analysis). The enzyme's interaction with heparin is characterized by low affinity, and extending XYLT2 fragments does not enhance binding, suggesting that multiple basic amino acid clusters are involved rather than a single binding site (Casanova2009Analysis).

In addition, XYLT2 activity is inhibited by nucleotides and glycosaminoglycans, with uridine-based nucleotides having a particularly strong inhibitory effect (Casanova2008Heterologous). This suggests that XYLT2 may participate in regulatory interactions within the glycosylation pathway.


## References


[1. (Matsuo2018Xylosylation) Kouki Matsuo and Go Atsumi. Xylosylation of proteins by expression of human xylosyltransferase 2 in plants. Journal of Bioscience and Bioengineering, 126(3):371–378, September 2018. URL: http://dx.doi.org/10.1016/j.jbiosc.2018.03.013, doi:10.1016/j.jbiosc.2018.03.013. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jbiosc.2018.03.013)

[2. (Casanova2009Analysis) Javier Carrera Casanova, Michael Ambrosius, Joachim Kuhn, Knut Kleesiek, and Christian Götting. Analysis of xylosyltransferase ii binding to the anticoagulant heparin. Biochemical and Biophysical Research Communications, 383(1):4–10, May 2009. URL: http://dx.doi.org/10.1016/j.bbrc.2009.03.050, doi:10.1016/j.bbrc.2009.03.050. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2009.03.050)

[3. (Munns2015Homozygosity) Craig F. Munns, Somayyeh Fahiminiya, Nabin Poudel, Maria Cristina Munteanu, Jacek Majewski, David O. Sillence, Jordan P. Metcalf, Andrew Biggin, Francis Glorieux, François Fassier, Frank Rauch, and Myron E. Hinsdale. Homozygosity for frameshift mutations in xylt2 result in a spondylo-ocular syndrome with bone fragility, cataracts, and hearing defects. The American Journal of Human Genetics, 96(6):971–978, June 2015. URL: http://dx.doi.org/10.1016/j.ajhg.2015.04.017, doi:10.1016/j.ajhg.2015.04.017. This article has 62 citations.](https://doi.org/10.1016/j.ajhg.2015.04.017)

[4. (Chouery2023Spondyloocular) Eliane Chouery, Rim Karam, Yves Najm Mrad, Cybel Mehawej, Nahia Dib El Jalbout, Jamal Bleik, Daniel Mahfoud, and Andre Megarbane. Spondyloocular syndrome: a report of an additional family and phenotypic spectrum delineation. Genes, 14(2):497, February 2023. URL: http://dx.doi.org/10.3390/genes14020497, doi:10.3390/genes14020497. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14020497)

[5. (Casanova2008Heterologous) Javier Carrera Casanova, Joachim Kuhn, Knut Kleesiek, and Christian Götting. Heterologous expression and biochemical characterization of soluble human xylosyltransferase ii. Biochemical and Biophysical Research Communications, 365(4):678–684, January 2008. URL: http://dx.doi.org/10.1016/j.bbrc.2007.10.206, doi:10.1016/j.bbrc.2007.10.206. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2007.10.206)

[6. (Müller2012First) Benjamin Müller, Christian Prante, Cornelius Knabbe, Knut Kleesiek, and Christian Götting. First identification and functional analysis of the human xylosyltransferase ii promoter. Glycoconjugate Journal, 30(3):237–245, August 2012. URL: http://dx.doi.org/10.1007/s10719-012-9439-5, doi:10.1007/s10719-012-9439-5. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10719-012-9439-5)

[7. (Fischer2020Xylosyltransferasedeficient) Bastian Fischer, Thanh-Diep Ly, Vanessa Schmidt, Doris Hendig, Joachim Kuhn, Cornelius Knabbe, and Isabel Faust. Xylosyltransferase-deficient human hek293 cells show a strongly reduced proliferation capacity and viability. Biochemical and Biophysical Research Communications, 521(2):507–513, January 2020. URL: http://dx.doi.org/10.1016/j.bbrc.2019.10.148, doi:10.1016/j.bbrc.2019.10.148. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2019.10.148)

[8. (Poönighaus2007Human) Claudia Poönighaus, Michael Ambrosius, Javier Carrera Casanova, Christian Prante, Joachim Kuhn, Jeffrey D. Esko, Knut Kleesiek, and Christian Goötting. Human xylosyltransferase ii is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. Journal of Biological Chemistry, 282(8):5201–5206, February 2007. URL: http://dx.doi.org/10.1074/jbc.m611665200, doi:10.1074/jbc.m611665200. This article has 87 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m611665200)

[9. (Doddato2021Spondyloocular) Gabriella Doddato, Alessandra Fabbiani, Chiara Fallerini, Mirella Bruttini, Theodora Hadjistilianou, Martino Landi, Caterina Coradeschi, Salvatore Grosso, Barbara Tomasini, Maria Antonietta Mencarelli, Alessandra Renieri, and Francesca Ariani. Spondyloocular syndrome: a novel xylt2 variant with description of the neonatal phenotype. Frontiers in Genetics, December 2021. URL: http://dx.doi.org/10.3389/fgene.2021.761264, doi:10.3389/fgene.2021.761264. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2021.761264)

[10. (Cuellar2007Biosynthesis) Karen Cuellar, Hoa Chuong, Sherry M. Hubbell, and Myron E. Hinsdale. Biosynthesis of chondroitin and heparan sulfate in chinese hamster ovary cells depends on xylosyltransferase ii. Journal of Biological Chemistry, 282(8):5195–5200, February 2007. URL: http://dx.doi.org/10.1074/jbc.M611048200, doi:10.1074/jbc.m611048200. This article has 85 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M611048200)